PHILADELPHIA - Researchers from the University of Pennsylvania School of Medicine and colleagues discovered that the Notch signaling pathway, which determines the development of many cell types, and is also implicated in some cancers, is not universally essential for the maintenance of stem cells. The findings appear this week in Cell Stem Cell, and indicate that inhibitors of Notch may not affect bone marrow stem cells.
Notch is one of a select set of proteins that influence the development of a wide variety of types of cells. Prior work has shown that increases in signals generated by Notch are important in certain human tumors, particularly some kinds of childhood leukemia, making Notch an attractive target for new cancer therapies. However, it has also been suggested that Notch is needed to maintain the stem cells in the bone marrow from which normal blood cells are formed, raising the concern that Notch inhibitors might destroy the normal bone marrow. “This potential risk raised important questions about treating leukemia patients with Notch inhibitors,” notes senior author Warren Pear, MD, PhD, Associate Professor of Pathology and Laboratory Medicine and the Abramson Family Cancer Research Institute.
Previous work from the Pear lab and others has shown that Notch signals are required for the proper development of lymphocytes. More importantly in terms of human disease, work done together with co-author Jon Aster’s lab at Harvard over the last decade has shown that abnormal increases in Notch signaling cause T-cell acute lymphoblastic leukemias, which make up about 15-20 percent of childhood leukemias. Growth of these leukemias can be stopped in the laboratory by new kinds of Notch pathway inhibitors.
“We have several projects focused on the development of new leukemia therapies that are designed to inhibit Notch,” notes Pear. “But it was important to know if this would have detrimental effects on bone marrow stem cells.”
This new work from the Pear group and colleagues showed definitively that adult bone marrow stem cells do not require Notch signals, indicating that it should be possible to give these inhibitors to patients without fear of causing bone marrow failure.
This work was funded by the National Cancer Institute and the National Institute of Allergy and Infectious Diseases, the Leukemia and Lymphoma Society, and the Damon Runyon Foundation. Additional co-authors are lead author Ivan Maillard (University of Michigan) Avinish Bhandoola (Penn) and Freddy Radtke (Switzerland).
PENN Medicine is a $3.5 billion enterprise dedicated to the related missions of medical education, biomedical research, and excellence in patient care. PENN Medicine consists of the University of Pennsylvania School of Medicine (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System.
Penn's School of Medicine is currently ranked #3 in the nation in U.S.News & World Report's survey of top research-oriented medical schools; and, according to most recent data from the National Institutes of Health, received over $379 million in NIH research funds in the 2006 fiscal year. Supporting 1,400 fulltime faculty and 700 students, the School of Medicine is recognized worldwide for its superior education and training of the next generation of physician-scientists and leaders of academic medicine.
The University of Pennsylvania Health System includes three hospitals — its flagship hospital, the Hospital of the University of Pennsylvania, rated one of the nation’s “Honor Roll” hospitals by U.S.News & World Report; Pennsylvania Hospital, the nation's first hospital; and Penn Presbyterian Medical Center — a faculty practice plan; a primary-care provider network; two multispecialty satellite facilities; and home care and hospice.
The Abramson Cancer Center (ACC) of the University of Pennsylvania is a national leader in cancer research, patient care, and education. The pre-eminent position of the Cancer Center is reflected in its continuous designation as a Comprehensive Cancer Center by the National Cancer Institute for 30 years, one of 39 such Centers in the United States. The ACC is dedicated to innovative and compassionate cancer care. The clinical program, comprised of a dedicated staff of physicians, nurse practitioners, nurses, social workers, physical therapists, nutritionists and patient support specialists, currently sees over 50,000 outpatient visits, 3400 inpatient admissions, and provides over 25,000 chemotherapy treatments, and more than 65,000 radiation treatments annually. Not only is the ACC dedicated to providing state-of-the-art cancer care, the latest forms of cancer prevention, diagnosis, and treatment are available to our patients through clinical themes that developed in the relentless pursuit to eliminate the pain and suffering from cancer. In addition, the ACC is home to the 300 research scientists who work relentlessly to determine the pathogenesis of cancer. Together, the faculty is committed to improving the prevention, diagnosis and treatment of cancer.
Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $5.3 billion enterprise.
The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 18 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $373 million awarded in the 2015 fiscal year.
The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center -- which are recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report -- Chester County Hospital; Lancaster General Health; Penn Wissahickon Hospice; and Pennsylvania Hospital -- the nation's first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Chestnut Hill Hospital and Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2015, Penn Medicine provided $253.3 million to benefit our community.